Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial

Kasper K Iversen; Børge Teisner; Per Winkel; Christian Gluud; Erik Kjøller; Hans Jørn Kolmos; Per Rossen Hildebrandt; Jørgen Hilden; Jens Kastrup; The CLARICOR Trial Group

doi:10.1016/j.atherosclerosis.2010.10.025

Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial

Kasper K Iversen, Børge Teisner, Per Winkel, Christian Gluud, Erik Kjøller, Hans Jørn Kolmos, Per Rossen Hildebrandt, Jørgen Hilden, Jens Kastrup, The CLARICOR Trial Group

Section of Biostatistics

35 Citations (Scopus)

Abstract

OBJECTIVE: Pregnancy associated plasma protein-A (PAPP-A) is a potential new marker for vulnerable plaques in the coronary arteries only examined in stable coronary disease (CAD) in patients undergoing coronary angiography. Here we address the prognostic value of serum PAPP-A in unselected stable CAD patients. METHOD: Blood samples were drawn at study entry. Serum PAPP-A values =4mIU/L were considered elevated. Mortality and non-fatal myocardial infarction was prospectively registered. The primary outcome was the composite outcome of myocardial infarction and all-cause mortality, secondary outcomes were all-cause mortality and myocardial infarction. RESULTS: Patients (n=4243) were followed for a median of 2.8 years. In a Cox analysis, elevated PAPP-A was significantly related to the composite outcome of myocardial infarction and death (HR 1.99, 95% CI 1.62-2.45, p

Original language	English
Journal	Atherosclerosis
Volume	214
Issue number	1
Pages (from-to)	203-208
Number of pages	6
ISSN	0021-9150
DOIs	https://doi.org/10.1016/j.atherosclerosis.2010.10.025
Publication status	Published - 1 Jan 2011

Access to Document

10.1016/j.atherosclerosis.2010.10.025

Cite this

Iversen, K. K., Teisner, B., Winkel, P., Gluud, C., Kjøller, E., Kolmos, H. J., Hildebrandt, P. R., Hilden, J., Kastrup, J., & The CLARICOR Trial Group (2011). Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial. Atherosclerosis, 214(1), 203-208. https://doi.org/10.1016/j.atherosclerosis.2010.10.025

Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial. / Iversen, Kasper K; Teisner, Børge; Winkel, Per et al.

In: Atherosclerosis, Vol. 214, No. 1, 01.01.2011, p. 203-208.

Research output: Contribution to journal › Journal article › Research › peer-review

Iversen, KK, Teisner, B, Winkel, P, Gluud, C, Kjøller, E, Kolmos, HJ, Hildebrandt, PR, Hilden, J, Kastrup, J & The CLARICOR Trial Group 2011, 'Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial', Atherosclerosis, vol. 214, no. 1, pp. 203-208. https://doi.org/10.1016/j.atherosclerosis.2010.10.025

@article{81f2afb31f4245ac873f02d242098992,

title = "Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial",

abstract = "OBJECTIVE: Pregnancy associated plasma protein-A (PAPP-A) is a potential new marker for vulnerable plaques in the coronary arteries only examined in stable coronary disease (CAD) in patients undergoing coronary angiography. Here we address the prognostic value of serum PAPP-A in unselected stable CAD patients. METHOD: Blood samples were drawn at study entry. Serum PAPP-A values =4mIU/L were considered elevated. Mortality and non-fatal myocardial infarction was prospectively registered. The primary outcome was the composite outcome of myocardial infarction and all-cause mortality, secondary outcomes were all-cause mortality and myocardial infarction. RESULTS: Patients (n=4243) were followed for a median of 2.8 years. In a Cox analysis, elevated PAPP-A was significantly related to the composite outcome of myocardial infarction and death (HR 1.99, 95% CI 1.62-2.45, p",

author = "Iversen, {Kasper K} and B{\o}rge Teisner and Per Winkel and Christian Gluud and Erik Kj{\o}ller and Kolmos, {Hans J{\o}rn} and Hildebrandt, {Per Rossen} and J{\o}rgen Hilden and Jens Kastrup and {The CLARICOR Trial Group}",

year = "2011",

month = jan,

day = "1",

doi = "10.1016/j.atherosclerosis.2010.10.025",

language = "English",

volume = "214",

pages = "203--208",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial

AU - Iversen, Kasper K

AU - Teisner, Børge

AU - Winkel, Per

AU - Gluud, Christian

AU - Kjøller, Erik

AU - Kolmos, Hans Jørn

AU - Hildebrandt, Per Rossen

AU - Hilden, Jørgen

AU - Kastrup, Jens

AU - The CLARICOR Trial Group

PY - 2011/1/1

Y1 - 2011/1/1

N2 - OBJECTIVE: Pregnancy associated plasma protein-A (PAPP-A) is a potential new marker for vulnerable plaques in the coronary arteries only examined in stable coronary disease (CAD) in patients undergoing coronary angiography. Here we address the prognostic value of serum PAPP-A in unselected stable CAD patients. METHOD: Blood samples were drawn at study entry. Serum PAPP-A values =4mIU/L were considered elevated. Mortality and non-fatal myocardial infarction was prospectively registered. The primary outcome was the composite outcome of myocardial infarction and all-cause mortality, secondary outcomes were all-cause mortality and myocardial infarction. RESULTS: Patients (n=4243) were followed for a median of 2.8 years. In a Cox analysis, elevated PAPP-A was significantly related to the composite outcome of myocardial infarction and death (HR 1.99, 95% CI 1.62-2.45, p

AB - OBJECTIVE: Pregnancy associated plasma protein-A (PAPP-A) is a potential new marker for vulnerable plaques in the coronary arteries only examined in stable coronary disease (CAD) in patients undergoing coronary angiography. Here we address the prognostic value of serum PAPP-A in unselected stable CAD patients. METHOD: Blood samples were drawn at study entry. Serum PAPP-A values =4mIU/L were considered elevated. Mortality and non-fatal myocardial infarction was prospectively registered. The primary outcome was the composite outcome of myocardial infarction and all-cause mortality, secondary outcomes were all-cause mortality and myocardial infarction. RESULTS: Patients (n=4243) were followed for a median of 2.8 years. In a Cox analysis, elevated PAPP-A was significantly related to the composite outcome of myocardial infarction and death (HR 1.99, 95% CI 1.62-2.45, p

U2 - 10.1016/j.atherosclerosis.2010.10.025

DO - 10.1016/j.atherosclerosis.2010.10.025

M3 - Journal article

C2 - 21093861

SN - 0021-9150

VL - 214

SP - 203

EP - 208

JO - Atherosclerosis

JF - Atherosclerosis

IS - 1

ER -

Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR Trial

Abstract

Access to Document

Fingerprint

Cite this